MTNB | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 3%

Liquidity 50%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.83%

1 Month

-4.60%

3 Months

-32.81%

6 Months

-64.01%

1 Year

8.88%

2 Year

132.05%

Key data

Stock price

$0.60

P/E Ratio

0.00

DAY RANGE

$0.58 - $0.62

EPS

-$1.79

52 WEEK RANGE

$0.47 - $3.09

52 WEEK CHANGE

$10.44

MARKET CAP

9.614 M

YIELD

N/A

SHARES OUTSTANDING

6.406 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

2.72

PUBLIC FLOAT

AVERAGE 10 VOLUME

$23,143

AVERAGE 30 VOLUME

$24,595

Company detail

CEO: Jerome D. Jabbour
Region: US
Website: matinasbiopharma.com
Employees: 30
IPO year: 2017

Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Matinas BioPharma Holdings, Inc. focuses on the discovery and development of various product candidates. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients.

MTNB - Matinas BioPharma Holdings, Inc.